Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan Children - Concepedia

Concepedia

Publication | Open Access

Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan Children

DOI Full Paper Access

64

Citations

20

References

2006

Year

Mark R. Withers, Denise McKinney, Bernhards Ogutu, John Waitumbi, Jessica Milman, Odika J. Apollo, Otieno G Allen, Kathryn Tucker, Lorraine Soisson, Carter L. Diggs,

PLoS Clinical Trials

Abstract

The FMP1/AS02A vaccine was safe and immunogenic in malaria-exposed 12- to 47-mo-old children and the magnitude of immune response of the 25 and 50 microg doses was superior to that of the 10 microg dose.

References

	Year	Citations

Page 1